{"id":18011,"date":"2016-10-06T00:00:00","date_gmt":"2016-10-06T04:00:00","guid":{"rendered":"http:\/\/fepada.org\/?p=18011"},"modified":"2018-05-09T19:16:05","modified_gmt":"2018-05-09T23:16:05","slug":"las-sustancias-y-metodos-prohibidos-en-todo-momento-dentro-y-fuera-de-la-competicion-important-2017-list-of-prohibited-substances-and-methods","status":"publish","type":"post","link":"https:\/\/fepada.org\/?p=18011","title":{"rendered":"Las sustancias y m\u00e9todos prohibidos en todo momento (Dentro y fuera de la competici\u00f3n)  IMPORTANT \/\/ 2017 List of Prohibited Substances and Methods"},"content":{"rendered":"<blockquote style=&quot;color: #212121; font-family: wf_segoe-ui_normal, &quot;>\n<div dir=&quot;ltr&quot;><span style=&quot;font-family: arial;&quot;>Estimada Se&ntilde;ora, Estimado Se&ntilde;or,&nbsp;<\/span><br style=&quot;font-family: arial;&quot; \/><br style=&quot;font-family: arial;&quot; \/><span style=&quot;font-family: arial;&quot;>2017 Lista de sustancias y m&eacute;todos prohibidos ya est&aacute; disponible.&nbsp;<\/span><span style=&quot;font-family: arial; text-decoration: underline;&quot;>Esta Lista entrar&aacute; en vigor el 1 de enero de 2017.&nbsp;<\/p>\n<p><\/span><span style=&quot;font-family: arial;&quot;>Se solicita a&nbsp;<\/span><span style=&quot;font-family: arial; text-decoration: underline;&quot;><strong>la<\/strong><\/span><span style=&quot;font-family: arial;&quot;>&nbsp;transmitir&aacute;&nbsp;<\/span><span style=&quot;font-family: arial; text-decoration: underline;&quot;><strong>a todos sus atletas.<\/strong><\/span><span style=&quot;font-family: arial;&quot;>&nbsp;<\/span><span style=&quot;font-family: arial; text-decoration: underline;&quot;><br \/><\/span><br style=&quot;font-family: arial;&quot; \/><span style=&quot;font-family: arial;&quot;>Cambios notables en comparaci&oacute;n con la Lista 2016 incluyen:&nbsp;<\/span><br style=&quot;font-family: arial;&quot; \/><br style=&quot;font-family: arial;&quot; \/><span style=&quot;font-family: arial; text-decoration: underline;&quot;><strong>Las sustancias y m&eacute;todos prohibidos en todo momento (Dentro y fuera de la competici&oacute;n)<\/strong><\/span><span style=&quot;font-family: arial;&quot;>&nbsp;<\/span><br style=&quot;font-family: arial;&quot; \/><strong style=&quot;font-family: arial;&quot;>SUSTANCIAS<\/strong><span style=&quot;font-family: arial;&quot;>&nbsp;<\/span><strong style=&quot;font-family: arial;&quot;>PROHIBITE<\/strong><span style=&quot;font-family: arial;&quot;>&nbsp;<\/span><strong style=&quot;font-family: arial;&quot;>D&nbsp;<br \/><em><br \/><\/em><\/strong><em style=&quot;font-family: arial;&quot;>AGENTES S1 ANAB&Oacute;LICOS<\/em><span style=&quot;font-family: arial;&quot;>&nbsp;<\/span><em style=&quot;font-family: arial;&quot;><br \/><\/em><em style=&quot;font-family: arial;&quot;>&bull; Los compuestos de boldenona, boldiona, norandrostenediona 19, y nandrolona se han transferido y 19-norandrostenediol a&ntilde;adido a la secci&oacute;n S1.b, ya que pueden ser producidos de manera end&oacute;gena a bajas concentraciones. Este cambio no afecta al estado prohibido de estas sustancias. La interpretaci&oacute;n y presentaci&oacute;n de informes de los resultados de estas sustancias se trata en todos los Documentos T&eacute;cnicos espec&iacute;ficos (TD2016IRMS y \/ o TD2016NA).<\/em><span style=&quot;font-family: arial;&quot;>&nbsp;<\/span><em style=&quot;font-family: arial;&quot;><br \/><\/em><em style=&quot;font-family: arial;&quot;>&bull; 5&alpha;-androst-2-eno-17-ona, conocido com&uacute;nmente como &quot;Delta-2&quot; o 2-androstenona, se a&ntilde;adi&oacute; como un ejemplo de metabolito de la DHEA, se encontr&oacute; m&aacute;s recientemente en los suplementos diet&eacute;ticos.<\/em><span style=&quot;font-family: arial;&quot;>&nbsp;<\/span><em style=&quot;font-family: arial;&quot;><\/em><em style=&quot;font-family: arial;&quot;><br \/><\/em><em style=&quot;font-family: arial;&quot;><br \/><\/em><em style=&quot;font-family: arial;&quot;>S2 Hormonas pept&iacute;dicas, factores de crecimiento y otras sustancias o mim&eacute;ticos RELACIONADOS<\/em><span style=&quot;font-family: arial;&quot;>&nbsp;<\/span><em style=&quot;font-family: arial;&quot;><br \/><\/em><em style=&quot;font-family: arial;&quot;>&bull; Para ampliar el alcance de los agentes estimulantes de eritropoy&eacute;tica, se a&ntilde;adieron los inhibidores de GATA (por ejemplo, K-11706) y &beta; factor de crecimiento transformante (TGF-&szlig;) (por ejemplo, inhibidores de sotatercept, luspatercept).<\/em><span style=&quot;font-family: arial;&quot;>&nbsp;<\/span><em style=&quot;font-family: arial;&quot;><br \/><\/em><em style=&quot;font-family: arial;&quot;>&bull; Se a&ntilde;adi&oacute; la Denominaci&oacute;n Com&uacute;n Internacional (DCI) del FG-4592, roxadustat.<\/em><span style=&quot;font-family: arial;&quot;>&nbsp;<\/span><em style=&quot;font-family: arial;&quot;><br \/><\/em><em style=&quot;font-family: arial;&quot;>&bull; Molidustat se a&ntilde;adi&oacute; como otro ejemplo de estabilizador de HIF.<\/em><span style=&quot;font-family: arial;&quot;>&nbsp;<\/span><em style=&quot;font-family: arial;&quot;><br \/><\/em><em style=&quot;font-family: arial;&quot;>&bull; Cobalto: Se reiter&oacute; que la vitamina B12, que contiene cobalto, no est&aacute; prohibido.<\/em><span style=&quot;font-family: arial;&quot;>&nbsp;<\/span><em style=&quot;font-family: arial;&quot;><br \/><\/em><em style=&quot;font-family: arial;&quot;><br \/><\/em><em style=&quot;font-family: arial;&quot;>S<\/em><span style=&quot;font-family: arial;&quot;>&nbsp;<\/span><em style=&quot;font-family: arial;&quot;>3<\/em><span style=&quot;font-family: arial;&quot;>&nbsp;<\/span><em style=&quot;font-family: arial;&quot;>beta-2-agonistas<\/em><span style=&quot;font-family: arial;&quot;>&nbsp;<\/span><em style=&quot;font-family: arial;&quot;><br \/><\/em><em style=&quot;font-family: arial;&quot;>&bull; Se simplifica la referencia a is&oacute;meros.<\/em><span style=&quot;font-family: arial;&quot;>&nbsp;<\/span><em style=&quot;font-family: arial;&quot;><br \/><\/em><em style=&quot;font-family: arial;&quot;>&bull; Se agregaron ejemplos de beta-2-agonistas selectivos y no selectivos (fenoterol, formoterol, higenamine, indacaterol, olodaterol, procaterol, reproterol, salbutamol, salmeterol, terbutalina, vilanterol).<\/em><span style=&quot;font-family: arial;&quot;>&nbsp;<\/span><em style=&quot;font-family: arial;&quot;><br \/><\/em><em style=&quot;font-family: arial;&quot;>&bull; Higenamine se documenta ser un constituyente de la planta Tinospora crispa, que se puede encontrar en algunos suplementos diet&eacute;ticos y es un no selectivo beta-2-agonista.<\/em><span style=&quot;font-family: arial;&quot;>&nbsp;<\/span><em style=&quot;font-family: arial;&quot;><br \/><\/em><em style=&quot;font-family: arial;&quot;>&bull; par&aacute;metros de dosificaci&oacute;n de salbutamol se refinaron para que quede claro que la dosis completa de 24 horas no debe administrarse al mismo tiempo.<\/em><span style=&quot;font-family: arial;&quot;>&nbsp;<\/span><em style=&quot;font-family: arial;&quot;><br \/><\/em><em style=&quot;font-family: arial;&quot;>&bull; La dosis m&aacute;xima para el salmeterol se declar&oacute; de acuerdo con las recomendaciones del fabricante.<\/em><span style=&quot;font-family: arial;&quot;>&nbsp;<\/span><em style=&quot;font-family: arial;&quot;><br \/><\/em><em style=&quot;font-family: arial;&quot;>&bull; Se est&aacute;n realizando estudios para establecer un umbral de concentraci&oacute;n urinaria apropiado para el salmeterol inhalado. En la actualidad, el Documento T&eacute;cnico TD2015MRPL recomienda no reportar salmeterol por debajo de 10 ng \/ mL.<\/em><span style=&quot;font-family: arial;&quot;>&nbsp;<\/span><em style=&quot;font-family: arial;&quot;><br \/><\/em><em style=&quot;font-family: arial;&quot;><br \/><\/em><em style=&quot;font-family: arial;&quot;>M&eacute;todos prohibidos<\/em><span style=&quot;font-family: arial;&quot;>&nbsp;<\/span><em style=&quot;font-family: arial;&quot;><br \/><\/em><em style=&quot;font-family: arial;&quot;>S4 hormonales y moduladores METAB&Oacute;LICOS<\/em><span style=&quot;font-family: arial;&quot;>&nbsp;<\/span><em style=&quot;font-family: arial;&quot;><br \/><\/em><em style=&quot;font-family: arial;&quot;>&bull; androsta-3,5-dieno-7,17-diona (arimistane) se a&ntilde;adi&oacute; como un nuevo ejemplo de inhibidor de la aromatasa.<\/em><span style=&quot;font-family: arial;&quot;>&nbsp;<\/span><em style=&quot;font-family: arial;&quot;><br \/><\/em><em style=&quot;font-family: arial;&quot;><br \/><\/em><em style=&quot;font-family: arial;&quot;>M1 MANIPULACI&Oacute;N DE LA SANGRE Y SUS COMPONENTES<\/em><span style=&quot;font-family: arial;&quot;>&nbsp;<\/span><em style=&quot;font-family: arial;&quot;><br \/><\/em><em style=&quot;font-family: arial;&quot;>&bull; El ox&iacute;geno suplementario administrado por inhalaci&oacute;n, pero no por v&iacute;a intravenosa, se permite. Para aclarar esto, M1.2 ahora lee &quot;con exclusi&oacute;n de ox&iacute;geno suplementario por inhalaci&oacute;n&quot;.<\/em><span style=&quot;font-family: arial;&quot;>&nbsp;<\/span><em style=&quot;font-family: arial;&quot;><br \/><\/em><em style=&quot;font-family: arial;&quot;><span style=&quot;text-decoration: underline;&quot;><strong><br \/><\/strong><\/span><\/em><span style=&quot;font-family: arial;&quot;>*****&nbsp;<\/span><br style=&quot;font-family: arial;&quot; \/><br style=&quot;font-family: arial;&quot; \/><em style=&quot;font-family: arial;&quot;><\/em><span style=&quot;font-family: arial; text-decoration: underline;&quot;><em><strong>Sustancias y m&eacute;todos prohibidos en competici&oacute;n<\/strong><\/em><\/span><span style=&quot;font-family: arial;&quot;>&nbsp;<\/span><em style=&quot;font-family: arial;&quot;><br \/><\/em><em style=&quot;font-family: arial;&quot;><br \/><\/em><em style=&quot;font-family: arial;&quot;>ESTIMULANTES S6<\/em><span style=&quot;font-family: arial;&quot;>&nbsp;<\/span><em style=&quot;font-family: arial;&quot;><br \/><\/em><em style=&quot;font-family: arial;&quot;>&bull; Lisdexanfetamina esta en S6.a; es un prof&aacute;rmaco inactivo de la anfetamina.<\/em><span style=&quot;font-family: arial;&quot;>&nbsp;<\/span><em style=&quot;font-family: arial;&quot;><br \/><\/em><em style=&quot;font-family: arial;&quot;>&bull; En ausencia de una denominaci&oacute;n com&uacute;n internacional para methylhexaneamine, se a&ntilde;adi&oacute; la Uni&oacute;n Internacional de Qu&iacute;mica Pura y Aplicada Nombre (IUPAC), 4-methylhexan-2-amina.<\/em><span style=&quot;font-family: arial;&quot;>&nbsp;<\/span><em style=&quot;font-family: arial;&quot;><br \/><\/em><em style=&quot;font-family: arial;&quot;>Un n&uacute;mero de otros sin&oacute;nimos existe para methylhexaneamine incluyendo: 1,3-dimethylamylamine, dimethylpentylamine; methylhexamine; metilhexanamina; 1,3-dimethylpentylamine.<\/em><span style=&quot;font-family: arial;&quot;>&nbsp;<\/span><em style=&quot;font-family: arial;&quot;><br \/><\/em><em style=&quot;font-family: arial;&quot;>&bull; Regular el consumo de alimentos no producir&aacute; suficientes niveles de feniletilamina para dar lugar a un resultado anal&iacute;tico adverso.<\/em><span style=&quot;font-family: arial;&quot;>&nbsp;<\/span><em style=&quot;font-family: arial;&quot;><br \/><\/em><em style=&quot;font-family: arial;&quot;><br \/><\/em><em style=&quot;font-family: arial;&quot;>S7 NARCOTICOS<\/em><span style=&quot;font-family: arial;&quot;>&nbsp;<\/span><em style=&quot;font-family: arial;&quot;><br \/><\/em><em style=&quot;font-family: arial;&quot;>&bull; Se a&ntilde;adi&oacute; nicomorfina. Es un f&aacute;rmaco analg&eacute;sico opioide, que se convierte a la morfina despu&eacute;s de la administraci&oacute;n.<\/em><span style=&quot;font-family: arial;&quot;>&nbsp;<\/span><em style=&quot;font-family: arial;&quot;><br \/><\/em><em style=&quot;font-family: arial;&quot;><br \/><\/em><em style=&quot;font-family: arial;&quot;>S9 GLUCOCORTICOIDES<\/em><span style=&quot;font-family: arial;&quot;>&nbsp;<\/span><em style=&quot;font-family: arial;&quot;><br \/><\/em><em style=&quot;font-family: arial;&quot;>&bull; Despu&eacute;s de considerar los comentarios de las partes interesadas, no se hicieron cambios en esta secci&oacute;n para 2017.<\/em><span style=&quot;font-family: arial;&quot;>&nbsp;<\/span><em style=&quot;font-family: arial;&quot;><br \/><\/em><em style=&quot;font-family: arial;&quot;><br \/>*****&nbsp;<\/p>\n<p><\/em><span style=&quot;font-family: arial; text-decoration: underline;&quot;><em><strong>Programa de monitoreo&nbsp;<\/p>\n<p><\/strong><\/em><\/span><em style=&quot;font-family: arial;&quot;><\/em><em style=&quot;font-family: arial;&quot;>Se a&ntilde;adi&oacute; lo siguiente para establecer patrones de uso:<\/em><span style=&quot;font-family: arial;&quot;>&nbsp;<\/span><em style=&quot;font-family: arial;&quot;><\/em><em style=&quot;font-family: arial;&quot;><br \/><\/em><em style=&quot;font-family: arial;&quot;>&bull; La code&iacute;na;<\/em><span style=&quot;font-family: arial;&quot;>&nbsp;<\/span><em style=&quot;font-family: arial;&quot;><br \/><\/em><em style=&quot;font-family: arial;&quot;>&bull; El uso simult&aacute;neo de m&uacute;ltiples beta-2-agonistas.<\/em><span style=&quot;font-family: arial;&quot;>&nbsp;<\/span><\/div>\n<div dir=&quot;ltr&quot;><\/div>\n<div dir=&quot;ltr&quot;><\/div>\n<div dir=&quot;ltr&quot;><span style=&quot;font-family: Arial; font-size: small;&quot;>Dear Madam, Dear Sir,<\/span><\/div>\n<\/blockquote>\n<blockquote style=&quot;color: #212121; font-family: wf_segoe-ui_normal, &quot;>\n<div dir=&quot;ltr&quot;>\n<div class=&quot;x_gmail_quote&quot;>\n<div><span><span style=&quot;font-family: Arial;&quot;><br \/>The 2017 List of Prohibited Substances and Methods is now available.&nbsp;<span style=&quot;text-decoration: underline;&quot;>This List will take effect on January 1, 2017.&nbsp;<\/p>\n<p><\/span>We kindly request you to forward this List&nbsp;<span style=&quot;text-decoration: underline;&quot;><strong>to all your athletes.<\/strong><\/span><span style=&quot;text-decoration: underline;&quot;><br \/><\/span><br \/>Noteworthy changes compared to the 2016 List include:<\/p>\n<p><span style=&quot;text-decoration: underline;&quot;><strong>Substances and methods prohibited at all times (In- and Out-of-Competition)<\/strong><\/span><br \/><strong>PROHIBITE<\/strong><strong>D SUBSTANCES<br \/><em><br \/><\/em><\/strong><em>S1 ANABOLIC AGENTS<\/em><em><br \/><\/em><em>&bull; Compounds boldenone, boldione, 19-norandrostenedione, and nandrolone have been transferred and 19-norandrostenediol added to the S1.b section because they can be produced endogenously at low concentrations. This change does not affect the prohibited status of these substances. The interpretation and reporting of findings for these substances is addressed in specific Technical Documents (TD2016IRMS and\/or TD2016NA).<\/em><em><br \/><\/em><em>&bull; 5&alpha;-androst-2-ene-17-one, commonly known as &ldquo;Delta-2&rdquo; or 2-androstenone, was added as an example of metabolite of DHEA, more recently found in dietary supplements.<\/em><em>&nbsp;<\/em><em><br \/><\/em><em><br \/><\/em><em>S2 PEPTIDE HORMONES, GROWTH FACTORS, RELATED SUBSTANCES AND MIMETICS<\/em><em><br \/><\/em><em>&bull; To extend the scope of Erythropoietic Stimulating Agents, GATA inhibitors (e.g. K-11706) and Transforming Growth Factor- &beta; (TGF-&beta;) inhibitors (e.g. sotatercept, luspatercept) were added.<\/em><em><br \/><\/em><em>&bull; The International Nonproprietary Name (INN) of FG-4592, roxadustat, was added.<\/em><em><br \/><\/em><em>&bull; Molidustat was added as another example of HIF stabilizer.<\/em><em><br \/><\/em><em>&bull; Cobalt: It is re-iterated that vitamin B12, which contains cobalt, is not prohibited.<\/em><em><br \/><\/em><em><br \/><\/em><em>S<\/em><em>3&nbsp;<\/em><em>BETA-2-AGONISTS<\/em><em><br \/><\/em><em>&bull; The reference to isomers was simplified.<\/em><em><br \/><\/em><em>&bull; Examples of selective and non-selective beta-2-agonists were added (fenoterol, formoterol, higenamine, indacaterol, olodaterol, procaterol, reproterol, salbutamol, salmeterol, terbutaline, vilanterol).<\/em><em><br \/><\/em><em>&bull; Higenamine is documented to be a constituent of the plant Tinospora crispa, which can be found in some dietary supplements and is a non-selective beta-2-agonist.<\/em><em><br \/><\/em><em>&bull; Dosing parameters of salbutamol were refined to make it clear that the full 24 hour dose should not be administered at one time.<\/em><em><br \/><\/em><em>&bull; The maximum dosage for salmeterol was stated according to the manufacturers&rsquo; recommendations.<\/em><em><br \/><\/em><em>&bull; Studies are ongoing to establish an appropriate urinary threshold concentration for inhaled salmeterol. At present, the Technical Document TD2015MRPL recommends not to report salmeterol below 10 ng\/mL.<\/em><em><br \/><\/em><em><br \/><\/em><em>PROHIBITED METHODS<\/em><em><br \/><\/em><em>S4 HORMONE AND METABOLIC MODULATORS<\/em><em><br \/><\/em><em>&bull; Androsta-3,5-diene-7,17-dione (arimistane) was added as a new example of aromatase inhibitor.<\/em><em><br \/><\/em><em><br \/><\/em><em>M1 MANIPULATION OF BLOOD AND BLOOD COMPONENTS<\/em><em><br \/><\/em><em>&bull; Supplemental oxygen administered by inhalation, but not intravenously, is permitted. To clarify this, M1.2 now reads &ldquo;excluding supplemental oxygen by inhalation&rdquo;.<\/em><em><br \/><\/em><em><span style=&quot;text-decoration: underline;&quot;><strong><br \/><\/strong><\/span><\/em>*****<\/p>\n<p><em><\/em><span style=&quot;text-decoration: underline;&quot;><em><strong>Substances and Methods Prohibited In-Competition<\/strong><\/em><\/span><em><br \/><\/em><em><br \/><\/em><em>S6 STIMULANTS<\/em><em><br \/><\/em><em>&bull; Lisdexamfetamine was added to S6.a; it is an inactive pro-drug of amfetamine.<\/em><em><br \/><\/em><em>&bull; In the absence of an INN for methylhexaneamine, its International Union of Pure and Applied Chemistry (IUPAC) name, 4-methylhexan-2-amine, was added.<\/em><em><br \/><\/em><em>A number of other synonyms exist for methylhexaneamine including: 1,3-dimethylamylamine, dimethylpentylamine; methylhexamine; methylhexanamine; 1,3-dimethylpentylamine.<\/em><em><br \/><\/em><em>&bull; Regular food consumption will not yield sufficient levels of phenylethylamine to result in an Adverse Analytical Finding.<\/em><em><br \/><\/em><em><br \/><\/em><em>S7 NARCOTICS<\/em><em><br \/><\/em><em>&bull; Nicomorphine was added. It is an opioid analgesic drug, which is converted to morphine following administration.<\/em><em><br \/><\/em><em><br \/><\/em><em>S9 GLUCOCORTICOIDS<\/em><em><br \/><\/em><em>&bull; After consideration of stakeholders&rsquo; comments, no changes were made in this section for 2017.<\/em><em><br \/><\/em><em><br \/>*****<\/p>\n<p><\/em><span style=&quot;text-decoration: underline;&quot;><em><strong>Monitoring Program<\/p>\n<p><\/strong><\/em><\/span><em><\/em><em>The following were added to establish patterns of use:<\/em><em>&nbsp;<\/em><em><br \/><\/em><em>&bull; Codeine;<\/em><em><br \/><\/em><em>&bull; Concurrent use of multiple beta-2-agonists.<\/em><\/span><\/span><\/div>\n<\/div>\n<\/div>\n<\/blockquote>\n<blockquote style=&quot;color: #212121; font-family: wf_segoe-ui_normal, &quot;>\n<div dir=&quot;ltr&quot;><span style=&quot;font-family: arial;&quot;><br \/><\/span><\/div>\n<\/blockquote>\n","protected":false},"excerpt":{"rendered":"<p>Estimada Se&ntilde;ora, Estimado Se&ntilde;or,&nbsp;2017 Lista de sustancias y m&eacute;todos prohibidos ya est&aacute; disponible.&nbsp;Esta Lista entrar&aacute; en vigor el 1 de enero de 2017.&nbsp; Se solicita a&nbsp;la&nbsp;transmitir&aacute;&nbsp;a todos sus atletas.&nbsp;Cambios notables en comparaci&oacute;n con la Lista 2016 incluyen:&nbsp;Las sustancias y m&eacute;todos prohibidos en todo momento (Dentro y fuera de la competici&oacute;n)&nbsp;SUSTANCIAS&nbsp;PROHIBITE&nbsp;D&nbsp;AGENTES S1 ANAB&Oacute;LICOS&nbsp;&bull; Los compuestos de [&hellip;]<\/p>\n","protected":false},"author":28,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[189],"tags":[],"class_list":["post-18011","post","type-post","status-publish","format-standard","hentry","category-formacion"],"acf":[],"_links":{"self":[{"href":"https:\/\/fepada.org\/index.php?rest_route=\/wp\/v2\/posts\/18011","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/fepada.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/fepada.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/fepada.org\/index.php?rest_route=\/wp\/v2\/users\/28"}],"replies":[{"embeddable":true,"href":"https:\/\/fepada.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=18011"}],"version-history":[{"count":1,"href":"https:\/\/fepada.org\/index.php?rest_route=\/wp\/v2\/posts\/18011\/revisions"}],"predecessor-version":[{"id":18075,"href":"https:\/\/fepada.org\/index.php?rest_route=\/wp\/v2\/posts\/18011\/revisions\/18075"}],"wp:attachment":[{"href":"https:\/\/fepada.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=18011"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/fepada.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=18011"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/fepada.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=18011"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}